What is GenScript ProBio?
Headquartered in Piscataway, New Jersey, GenScript ProBio operates as a critical player in the Research & Development industry. With a workforce ranging between 1,000 and 4,999 employees and annual revenue figures between 50M and 100M, the company has established itself as a vital partner for biopharmaceutical innovation. The firm specializes in providing comprehensive solutions that bridge the gap between early-stage discovery and commercial-scale manufacturing, effectively serving as a backbone for modern therapeutic development. Its market position is defined by a commitment to technical excellence and a scalable infrastructure that supports complex biological projects.
How much funding has GenScript ProBio raised?
GenScript ProBio has raised a total of $220M across 1 funding round:
Series C
$220M
Series C (2023): $220M with participation from Legend Capital
Key Investors in GenScript ProBio
Legend Capital
Legend Capital is a prominent private equity firm and a member of Legend Holdings, managing significant USD and RMB funds with a focus on innovation-driven enterprises.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for GenScript ProBio?
With the infusion of this major strategic investment, GenScript ProBio is expected to prioritize the scaling of its manufacturing facilities and the enhancement of its proprietary technology platforms. The company's roadmap likely involves deepening its service offerings to meet the rising demand for high-quality biological reagents and viral vector production. As the firm transitions into this next phase of growth, stakeholders will be monitoring its ability to maintain operational efficiency while navigating the complexities of the global life sciences supply chain. This capital deployment serves as a catalyst for long-term value creation and sustained market leadership.
See full GenScript ProBio company page
